These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9058744)

  • 21. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
    Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
    Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capacity of genetically different T lymphocytes to induce lethal graft-versus-host disease correlates with their capacity to generate suppression but not with their capacity to generate anti-F1 killer cells. A non-H-2 locus determines the inability to induce lethal graft-versus-host disease.
    Van Elven EH; Rolink AG; Veen FV; Gleichmann E
    J Exp Med; 1981 Jun; 153(6):1474-88. PubMed ID: 6454750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
    Hsieh MH; Patterson AE; Korngold R
    Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo.
    Umansky V; Beckhove P; Rocha M; Krüger A; Crocker PR; Schirrmacher V
    Immunology; 1996 Feb; 87(2):303-9. PubMed ID: 8698395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms.
    Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
    Transplantation; 1999 Feb; 67(3):444-50. PubMed ID: 10030293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide.
    Truitt RL; Rose WC; Rimm AA; Bortin MM
    Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
    Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
    Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor CD8 T cells and IFN-gamma are critical for sex-based differences in donor CD4 T cell engraftment and lupus-like phenotype in short-term chronic graft-versus-host disease mice.
    Foster AD; Soloviova K; Puliaeva I; Puliaiev M; Puliaev R; Finkelman F; Via CS
    J Immunol; 2011 Jun; 186(11):6238-54. PubMed ID: 21531893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice.
    Van Rappard-Van Der Veen FM; Radaszkiewicz T; Terraneo L; Gleichmann E
    J Immunol; 1983 Jun; 130(6):2693-701. PubMed ID: 6602176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
    Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
    Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.